Germany – Pharmaceutical products – Abschluss nicht-exklusiver Vereinbarungen über Arzneimittel mit dem Wirkstoff Relugolix (ATC-Code: L02BX04) im Wege eines Open-House-Modells

The subject of this publication is the conclusion of non-exclusive agreements for medicinal products with the active substance Relugolix (ATC Code: L02BX04). The contract conclusion takes place within the framework of an so-called Open-House model, i.e. a contract conclusion is open to all interested pharmaceutical companies within the participation period, provided they meet and accept the participation requirements. This means that individual contract negotiations are not conducted and (supply) exclusivity is not given. It is pointed out that the order quantity is unknown, as it depends on demand and the development of the number of insured persons, on the prescribing behaviour of doctors and on the dispensing and stocking behaviour of public pharmacies. Minimum order quantities are therefore not guaranteed. Interested pharmaceutical entrepreneurs can download the participation documents via the project room of the German Tender Portal (DTVP). To do this, an application for access to the project room is first required. After activation by the contracting entity, the participation documents can then be accessed. Absolute confidentiality must be maintained regarding the content of the participation documents - in particular regarding the content of the agreement and the discounts mentioned therein. Full or partial disclosure or provision of contents of the participation documents to or for third parties requires the prior written consent of the contracting entity. If participation is waived, all documents must be destroyed immediately in accordance with data protection regulations. The documents to be submitted are derived from the documents "Cover Letter" and "Explanations of the Contract Terms" stored in the project room. Communication, including the transmission of the participation documents, is carried out electronically via the tender portal DTVP; details can be found in the aforementioned documents. Any contradictory information in the contract notice is due to technical reasons and does not constitute a binding statement. Participation applications can be submitted for the first time by 5 March 2026. All further submission deadlines can be found in the annex "Submission Deadlines" stored in the project room. If the deadline falls on a Saturday, Sunday or a public holiday nationwide, the next working day shall take the place of such a day. In the event of late receipt, the submitted participation applications will be considered for the next submission deadline. The agreement ends, regardless of the date of the contract conclusion, at the latest on 31 December 2027. The contracting entity reserves the right to terminate the Open-House procedure prematurely, in particular in the event of the conclusion of exclusive agreements; in this case, the agreements already concluded end in accordance with the contractual provisions. According to the experience of the contracting entity, exclusive agreements generally come into force 8 to 12 months after the publication of the corresponding contract notice in the Supplement to the Official Journal of the European Union.